Technical Analysis for AGE - AgeX Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Uptrend | Bullish | 0.00% | |
Jack-in-the-Box Bullish | Bullish Swing Setup | 0.00% | |
Wide Range Bar | Range Expansion | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Crossed Above 200 DMA | Bullish | -24.27% | |
Golden Cross | Bullish | -24.27% |
Alert | Time |
---|---|
Possible Inside Day | about 8 hours ago |
60 Minute Opening Range Breakdown | about 11 hours ago |
Down 5% | about 13 hours ago |
Down 3% | about 13 hours ago |
Down 2 % | about 13 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/29/2024
AgeX Therapeutics, Inc. Description
AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which AgeX plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, AgeX, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. AgeX also markets Cytiva® comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Disease Clinical Development Stem Cell Cell Biology Product Design Algorithms Degenerative Disease Cloning Tissue Engineering Developmental Biology Telomerase
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 22.32 |
52 Week Low | 0.3104 |
Average Volume | 82,871 |
200-Day Moving Average | 0.77 |
50-Day Moving Average | 1.16 |
20-Day Moving Average | 2.31 |
10-Day Moving Average | 4.25 |
Average True Range | 2.01 |
RSI (14) | 78.77 |
ADX | 28.92 |
+DI | 72.55 |
-DI | 0.23 |
Chandelier Exit (Long, 3 ATRs) | 16.29 |
Chandelier Exit (Short, 3 ATRs) | 6.37 |
Upper Bollinger Bands | 13.97 |
Lower Bollinger Band | -9.34 |
Percent B (%b) | 1.13 |
BandWidth | 1007.77 |
MACD Line | 2.68 |
MACD Signal Line | 0.82 |
MACD Histogram | 1.8582 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 27.16 | ||||
Resistance 3 (R3) | 27.72 | 24.85 | 25.45 | ||
Resistance 2 (R2) | 24.85 | 22.24 | 24.58 | 24.88 | |
Resistance 1 (R1) | 20.88 | 20.63 | 19.45 | 20.32 | 24.31 |
Pivot Point | 18.01 | 18.01 | 17.30 | 17.74 | 18.01 |
Support 1 (S1) | 14.04 | 15.40 | 12.61 | 13.48 | 9.49 |
Support 2 (S2) | 11.17 | 13.79 | 10.90 | 8.92 | |
Support 3 (S3) | 7.20 | 11.17 | 8.35 | ||
Support 4 (S4) | 6.64 |